The effect of sulindac on arylamine N-acetyl-transferase activity in Pseudomonas aeruginosa

Microbios

Volumn 93, Issue 376, 1998, Pages 159-168

  Lo, Hsueh Hsia ^a   Hsieh, Sue Er ^a   Chung, Jing Gung ^b  

^a Chungtai Junior College of Medical Technology   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

N acetytransferase; P. aeruginosa; Sulindac

Indexed keywords

2 FLUORENYLAMINE; 2-AMINOFLUORENE; ARYLAMINE ACETYLTRANSFERASE; BACTERIAL PROTEIN; CARCINOGEN; FLUORENE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC;

ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METABOLISM; PSEUDOMONAS AERUGINOSA; TIME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYLAMINE N-ACETYLTRANSFERASE; BACTERIAL PROTEINS; CARCINOGENS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLUORENES; HUMANS; PSEUDOMONAS AERUGINOSA; SULINDAC; TIME FACTORS;

EID: 0031608464     PISSN: 00262633     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. BEAZER-BARCLAY Y, Levy D. B., Moser A. R., Dove W. F., Hamilton S. R., Vogelstein B. and Kinzler K. W. 1996. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis 17 1757-60.
2. BELANGER P. M. and Atsite-Gbeassor A. 1985. Effect of nonsteroidal antiinflammatory drugs on the microsomal mono-oxygenase system of rat liver. Can. J Physiol. Pharmacol. 63 798-803.
3. BELL D. A., Badawi A. F., Lang N. P., Ilett K. F., Kadlubar F. F. and Hirvonen A. 1995a. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of WAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res. 55 5226-9.
4. BELL D. A., Stephens E. A., Castranio T., Umbach D. M., Watson M., Deakin M., Elder J., Hendricks C., Duncan H. and Strange R. C. 1995b. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res. 55 3537-42.
5. BOOLBOL S. K., Dannenberg A. J., Chadburn A., Martucci C., Guo X. J., Ramonetti J. T., Abreu-Goris M., Newmark H. L., Lipkin M. L, DeCosse J. J. and Bertagnolli M. M. 1996. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 56 2556-60.
6. CHANG F. C. and Chung J. G. 1997. Evidence for arylamine N-acetyltransferase in the bacteria Escherichia coli. Curr. Microbiol. 36 125-30.
7. s-slow acetylator congenic mice. Drug Metab. Dispos. 21 1057-63.
8. CHUNG J. G., Lo H. H., Hsieh S. E. and Yen Y. S. 1997. Ibuprofen inhibits arylamine N-acetyltransferase in Klebsiella pneumonias. Curr. Microbiol. 35 195-200.
9. CLELAND W. W. 1967. The statistical analysis of enzyme kinetics data. Adv. Enzymol. Relat. Areas Mol. Biol. 29 1-32.
10. GIARDELLO F. M., Hamilton S. R., Krush A. J., Piantadosi S., Hylind L. M., Celano P., Booker S. V., Robinson C. R. and Offerhaus G. J. 1993. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328 1313-6.
11. GRANT D. M., Blum M., Beer M. and Meyer U. A. 1991. Monomorphic and polymorphic human arylamine N-acetyltransferase: a comparison of liver isozymes and expressed products of two cloned genes. Mol. Pharmacol. 39 184-91.
12. HANIF R., Pittas A., Feng Y., Koutsos M. I., Qiao L., Staiano-Coico L., Sniff S. I. and Rigas B. 1996. Effects of nonsteroidal antiinflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 52 237-45.
13. HEIN D. W., Doll M. A., Rustan T. D., Gray K., Feng Y., Ferguson R. J. and Grant D. W. 1993. Metabolic activation and detoxication of arylamine carcinogens by recombinant human NAT1 and NAT2 acetyltransferases. Carcinogenesis 14 1633-8.
14. HSIEH S. E., Lo H. H. and Chung J. G. 1998. The characteristics of arylamine W-acetyltransferase in Pseudomonas aeruginosa. Curr. Microbiol. 36 353-60.
15. HSIEH S. E., Lo H. H., Yen Y. S. and Chung J. G. 1997. The effect of vitamin C on N-acetyltransferase activity in Klebsiella pneumoniae. Food Chem. Toxicol. 35 1151-7.
16. JACOBY R. F., Marshall D. J., Newton M. A., Novakovic K., Tutsch K., Cole C. E., Lubet R. A., Kelloff G. J., Verma A., Moser A. R. and Dove W. F. 1996. Chemoprevention of spontaneous intestinal adenomas in the Ape Min mouse model by the nonsteroidal antiinflammatory drug piroxicam. Cancer Res. 56 710-4.
17. LANG N. P., Chu Z. J., Hunter C. F., Kendall D. C., Flammang T. J. and Kadlubar F. F. 1986. Role of aromatic amine acetyltransferase in human colorectal cancer. Arch. Surg. 121 1259-61.
18. LAYBAYLE D., Fischer D., Vielh P., Frouhin F., Pariente A., Bories C., Duhamael O., Trousset M. and Atti P. 1991. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101 635-9.
19. LO H. H., Yen Y. S., Hsieh S. E. and Chung J. G. 1997. Glycyrrhizic acid inhibits arylamine N-acetyltransferase in Klebsiella pneumoniae. J. appl. Toxicol. 17 385-90.
20. MATTANO S. S. and Weber W. W. 1987. Kinetics of arylamine N-acetyltransferase in tissues from rapid and slow acetylator mice. Carcinogenesis 8 133-7.
21. OHSAKO S. and Deguchi T. 1990. Cloning and expression of cDNAs for polymorphic and monomorphic N-acetyltransferase from human liver. J. biol. Chem. 265 4630-4.
22. OKUMURA F., Ueda O., Kitamuru S. and Tatsumi K. 1995. N-acetylation and N-formylation of carcinogenic arylamines and related compounds in dogs. Carcinogenesis 16 71-6.
23. RAO C. V., Rivenson A., Simi B., Zang E., Kelloff G., Steele V. and Reddy B. S. 1995. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal antiinflammatory agent. Cancer Res. 55 1464-72.
24. REDDY B. S., Tokumo K., Kulkarni N., Aligia C. and Kelloff G. 1992. Inhibition of colon Carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 16 1019-23.
25. ROBERTS-THOMSON I. C., Ryan P., Khoo K. K., Hart W. J., McMichael A. J. and Butler R. N. 1996. Diet, acetylator phenotype, and risk of colorectal neoplasia. Lancet 347 1372-4.
26. SANO H., Kawahito Y., Wilder R. L., Hashiramoto A., Mukai S., Asai K., Kimura S., Kato H., Kondo M. and Hla T. 1995. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 55 3785-9.
27. STRONG H. A., Warner N. J., Renwick A. G. and George C. F. 1985. Sulindac metabolism: the importance of an intact colon. Clin, pharmacol. Ther. 38 387-93.
28. VAN LIESHOUT E. M. M., Tiemessen D. M., Peters W. H. M. and Jansen J. B. M. J. 1997. Effects of nonsteroidal anti-inflammatory drugs on glutathione transferases of the rat digestive tract. Carcinogenesis 18 485-90.
29. WADDELL W. R. and Loughry R. W. 1983. Sulindac for polyposis of the colon. J. Surg. Oncol. 24 83-7.
30. WAKABAYASHI K., Nagao M., Esumi H. and Sugimura T. 1992. Food-derived mutagens and carcinogens. Cancer Res. 52 2092s-8s.
31. WARGOVICH M. J., Chen C. D., Harris C., Yang E. and Velasco M. 1995. Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon. Int. J. Cancer 60 515-9.
32. WATANABE M., Ishidate M. and Nohmi T. 1990. Sensitive method for the detection of mutagenic nitroarenes and aromatic amines: new derivatives of S. typhimurium tester strains possessing elevated O-acetyltransferase levels. Mutat. Res. 234 337-48.
33. 69 residue in the catalytic mechanism of N-hydroxyarylamine O-acetyltransferase of Salmonella typhimurium: sequence similarity at the amino acid level suggests a common catalytic mechanism of acetyltransferase for S. typhimurium and higher organisms. J. biol. Chem. 267 8429-36.
34. WEBER W. W. and Hein D. W. 1985. N-acetylation pharmacogenetics. Pharmacol. Rev. 37 25-79.